Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials

SIMPLE SUMMARY: In patients with advanced hepatocellular carcinoma, systemic therapy is recommended by most treatment guidelines. Sorafenib and lenvatinib are both 1st-line treatments for inoperable advanced HCC. Regorafenib, cabozantinib, and ramucirumab have been approved as 2nd-line targeted ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Bang-Bin, Lin, Zhong-Zhe, Shao, Yu-Yun, Hsu, Chiun, Hsu, Chih-Hung, Cheng, Ann-Lii, Liang, Po-Chin, Shih, Tiffany Ting-Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508238/
https://www.ncbi.nlm.nih.gov/pubmed/34638446
http://dx.doi.org/10.3390/cancers13194962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508238/
https://www.ncbi.nlm.nih.gov/pubmed/34638446
http://dx.doi.org/10.3390/cancers13194962

Ejemplares similares